Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep F Nomdedeu

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Experimental Hematology|February 22, 2025
D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1Sabina Cisa-Wieczorek, Maria Isabel Hernández-Alvarez, Matilde Parreño, et al.
Molecular Cancer Therapeutics|May 30, 2006
Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by MycMatilde Parreño, Jose P Vaqué, Isolda Casanova, et al.
Cancer Cell|June 15, 2007
Role of the polycomb repressive complex 2 in acute promyelocytic leukemiaRaffaella Villa, Diego Pasini, Arantxa Gutierrez, et al.
Oncotarget|November 5, 2017
<i>NEDD9</i>, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patientsVictor Pallarès, Montserrat Hoyos, M Carmen Chillón, et al.
Blood Advances|September 13, 2021
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1Guadalupe Oñate, Alex Bataller, Ana Garrido, et al.
European Journal of Haematology|May 8, 2013
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseMontserrat Hoyos, Josep F Nomdedeu, Jordi Esteve, et al.
Cancers|November 16, 2018
Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid LeukemiaVictor Pallarès, Montserrat Hoyos, M Carmen Chillón, et al.
British Journal of Haematology|June 9, 2020
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual diseaseAlex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, et al.
Blood Cancer Journal|January 11, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM GroupGuadalupe Oñate, Ana Garrido, Montserrat Arnan, et al.
Hemasphere|October 16, 2023
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic SyndromesAdrian Mosquera Orgueira, Manuel Mateo Perez Encinas, Nicolas A Diaz Varela, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Experimental Hematology|February 22, 2025
D816V KIT mutation induces mitochondrial morphologic and functional changes through BNIP3 downregulation in human myeloid cell lines ROSA and TF-1Sabina Cisa-Wieczorek, Maria Isabel Hernández-Alvarez, Matilde Parreño, et al.
Molecular Cancer Therapeutics|May 30, 2006
Novel triiodophenol derivatives induce caspase-independent mitochondrial cell death in leukemia cells inhibited by MycMatilde Parreño, Jose P Vaqué, Isolda Casanova, et al.
Cancer Cell|June 15, 2007
Role of the polycomb repressive complex 2 in acute promyelocytic leukemiaRaffaella Villa, Diego Pasini, Arantxa Gutierrez, et al.
Oncotarget|November 5, 2017
<i>NEDD9</i>, an independent good prognostic factor in intermediate-risk acute myeloid leukemia patientsVictor Pallarès, Montserrat Hoyos, M Carmen Chillón, et al.
Blood Advances|September 13, 2021
Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1Guadalupe Oñate, Alex Bataller, Ana Garrido, et al.
European Journal of Haematology|May 8, 2013
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseMontserrat Hoyos, Josep F Nomdedeu, Jordi Esteve, et al.
Cancers|November 16, 2018
Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid LeukemiaVictor Pallarès, Montserrat Hoyos, M Carmen Chillón, et al.
British Journal of Haematology|June 9, 2020
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual diseaseAlex Bataller, Guadalupe Oñate, Marina Diaz-Beyá, et al.
Blood Cancer Journal|January 11, 2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM GroupGuadalupe Oñate, Ana Garrido, Montserrat Arnan, et al.
Hemasphere|October 16, 2023
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic SyndromesAdrian Mosquera Orgueira, Manuel Mateo Perez Encinas, Nicolas A Diaz Varela, et al.
Pageof 3